Filgrastim, lenograstim and pegfilgrastim in the mobilization of peripheral blood progenitor cells in patients with lymphoproliferative malignancies.

This study looked for differences in hematopoietic peripheral stem cells (HPSCs) mobilization in response to the three available G-CSFs, namely lenograstim, filgrastim, and pegfilgrastim. Between 2000 and 2012, 146 patients (66 M and 80 F) who underwent ASCT for multiple myeloma, non-Hodgkin's lymphoma or Hodgkin's lymphoma were studied. All patients received induction therapy and then a mobilization regimen with cyclophosphamide plus lenograstim, or filgrastim, or pegfilgrastim. From days 12 to 14, HPSCs were collected by two to three daily leukaphereses. Our results show that high-dose cyclophosphamide plus lenograstim achieved adequate mobilization and the collection target more quickly and with fewer leukaphereses as compared to filgrastim and pegfilgrastim. No differences between the three regimens were observed regarding toxicity and days to WBC and platelet recovery. Thus, lenograstim may represent the ideal G-CSF for PBSC mobilization in patients with lymphoproliferative diseases. Further studies are needed to confirm these results and better understand the biological bases of these differences. PMID: 24722996 [PubMed - as supplied by publisher]
Source: Clinical Lymphoma and Myeloma - Category: Cancer & Oncology Authors: Tags: Clin Exp Med Source Type: research

Related Links:

Publication date: Available online 2 October 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Avyakta Kallam, Julie M. VoseAbstractNon-Hodgkin lymphomas that are refractory to or relapse after frontline chemoimmunotherapy have a poor prognosis. Although high dose chemotherapy, followed by autologous stem cell transplantation remains the standard of care at relapse, this treatment modality leads to a cure in less than 50% of the patients. Adoptive cellular immunotherapy with anti CD 19 chimeric antigen receptor (CAR) T cell has changed the treatment landscape in B cell lymphomas. They have emerged as effective t...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Autologous hematopoietic cell transplantation (Auto-HCT) following high dose chemotherapy has an important role in treating many patients with lymphoma and multiple myeloma. For patients with a variety of lymphomas including Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL), Auto-HCT might potentially be a curative procedure, in addition to improving overall survival (OS) and progression free survival (PFS) [1-5]. For multiple myeloma, Auto-HCT is not curative, but its role is well-established as a consolidation treatment to achieve deep durable remissions in the majority of patients [6-9].
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
Autologous hematopoietic cell transplantation (auto-HCT) following high-dose chemotherapy has an important role in treating many patients with lymphoma and multiple myeloma. For patients with a variety of lymphomas, including Hodgkin disease (HD) and non-Hodgkin lymphoma (NHL), auto-HCT might potentially be a curative procedure, in addition to improving overall survival and progression-free survival [1 –5]. For multiple myeloma, auto-HCT is not curative, but its role is well established as a consolidation treatment to achieve deep durable remissions in most patients [6–9].
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
Publication date: Available online 30 March 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Young-Woo Jeon, Seugyun Yoon, Gi June Min, Sung-Soo Park, Silvia Park, Jae-Ho Yoon, Sung-Eun Lee, Byung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Hee-Je Kim, Seok Lee, Chang-Ki Min, Jong Wook Lee, Seok-Goo ChoAbstractIntroductionAllogeneic hematopoietic stem cell transplant with reduced-intensity conditioning is an effective therapeutic option for patients with refractory or relapsed aggressive non-Hodgkin lymphoma (NHL).Patients and MethodsWe retrospectively evaluated survival outcomes and the efficacy of our fludarabine/mel...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Discussion In this section, we discuss the mechanisms responsible for lymphomagenesis in the various inborn errors of immunity and provide an overview of the treatment. Defects in Immune Responses That Predispose to Lymphomagenesis in PIDDs The complex immune mechanisms and their interplay that predisposes to neoplastic transformation of B or T cells and development of lymphomas in PIDD patients has not been fully elucidated. However, it is expected that the etiology in most cases is multifactorial and related to a dynamic regulation of immune response and environmental triggers (Figure 3). An underlying intrinsic susce...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
In this study, we investigated association of serum B2MG level changes with survival outcomes in PCNSL patients during induction chemotherapy who had elevated serum B2MG level at diagnosis.Methods We retrospectively reviewed prospectively collected PCNSL registry data for patients treated from March 1993 to May 2017 at Asan Medical Center in Seoul, Korea. Patients with serum B2MG of ≥ 1.8 μg/mL at diagnosis who had at least two or more measurement of serum B2MG including at diagnosis, 6 weeks, and 3 months from the initiation of induction chemotherapy were included in the analysis. Two weeks of window period was allo...
Source: Blood - Category: Hematology Authors: Tags: 627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)-Results from Retrospective/Observational Studies: Poster II Source Type: research
BACKGROUND: High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is now standard of care for newly diagnosed patients with multiple myeloma (MM) and is used for some forms of non-Hodgkin lymphoma, providing improved outcomes. ASCT has been associated with a high incidence of engraftment syndrome (ES), which clinically presents as skin rashes, diarrhea, non-infectious fevers, and capillary leak syndrome in the peri-engraftment period. ES can be a severe and potentially lethal complication in patients who do not respond to corticosteroid therapy.RATIONALE: Prior to stem cell collection, MM and lymph...
Source: Blood - Category: Hematology Authors: Tags: 723. Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence: Poster III Source Type: research
Background: Based on cohort studies and a limited number of prospective studies, physical activity (PA) can improve quality of life (QoL) in non-Hodgkin lymphoma (NHL), multiple myeloma (MM), and patients (pts) undergoing autologous stem cell transplant (ASCT). There are also data to suggest that survival (Pophali et al, ASH 2017) is improved with increased PA in NHL pts. After ASCT, it is known that QoL and physical function will decrease. PA has been linked to improved QoL outcomes for pts undergoing ASCT. Recently, evidence shows fitness trackers can help monitor and improve adherence to PA in cancer pts. We aim to stud...
Source: Blood - Category: Hematology Authors: Tags: 904. Outcomes Research-Malignant Conditions Source Type: research
Autologous transplantation of hematopoietic stem cells (HSCs) is a widely used strategy for hematologic and immunologic recovery after high-dose chemotherapy for hematologic malignancies, such as multiple myeloma (MM), non-Hodgkin lymphoma, Hodgkin disease, and other cancers, including germ cell tumor and neuroblastoma [1]. After chemotherapy induction, regardless of whether or not the chemotherapy has been accompanied by cytokine (usually granulocyte colony stimulating factor [G-CSF]) treatment, or after the patient has received treatment with a cytokine alone (such as G-CSF) without associated chemotherapy, HSCs for tran...
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
Autologous transplantation of hematopoietic stem cells (HSCs) is a widely used strategy for hematologic and immunologic recovery following high-dose chemotherapy for hematologic malignancies, such as multiple myeloma (MM), non-Hodgkin lymphoma, Hodgkin's disease, and other cancers, including germ-cell tumor and neuroblastoma [1]. After the induction of patients ’ chemotherapy, regardless of whether or not the chemotherapy has been accompanied by cytokine (usually granulocyte colony stimulating factor [G-CSF]) treatment, or after the patient has received treatment with a cytokine alone (such as G-CSF) without associat...
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
More News: Cancer & Oncology | Chemotherapy | Filgrastim | Hodgkin's Disease | Lymphoma | Myeloma | Neulasta | Neupogen | Non-Hodgkin's Lymphoma | Stem Cell Therapy | Stem Cells | Study | Toxicology | Transplants